Hi-Glitazone 30 Mg Tablets

Hi-Glitazone 30 Mg Tablets

Description:

Hi-Glitazone 30 mg tablets are an oral anti-diabetic prescription medicine containing pioglitazone, a thiazolidinedione (TZD) insulin sensitizer. They are used as part of a comprehensive diabetes care plan, including diet and exercise, to improve blood glucose control in adults with type 2 diabetes mellitus. By enhancing the body’s sensitivity to insulin, Hi-Glitazone 30 mg helps reduce fasting and postprandial blood sugar levels and supports long-term glycaemic control (HbA1c reduction). This product is classified as a medicine under diabetes care and should be used only under medical supervision.

Indications:

• Type 2 diabetes mellitus (non–insulin-dependent diabetes) in adults, particularly in patients with insulin resistance.
• Used to improve glycaemic control when diet and exercise alone are insufficient.
• May be used as monotherapy or in combination with other oral anti-diabetic agents (such as metformin, sulfonylureas) or insulin, as prescribed by a physician.
• Helps reduce elevated fasting blood glucose, postprandial blood glucose, and HbA1c levels.

Active Ingredients / Key Components:

• Pioglitazone – 30 mg per tablet.
• Excipients: The full list of inactive ingredients (excipients, binders, fillers, colorants, preservatives) is not available in the provided information. Please refer to the official package insert for complete composition.

Dosage & Administration / How to Use:

• Recommended dose: Typically 15–30 mg once daily, which may be adjusted by the physician up to a maximum usual dose of 45 mg once daily, depending on response and tolerability. Hi-Glitazone 30 mg represents a commonly used strength; the exact dose must be individualized by the doctor.
• Administration: Swallow the tablet whole with a glass of water. Do not crush or chew unless advised by your healthcare provider.
• With or without food: Hi-Glitazone 30 mg tablets may be taken with or without food, preferably at the same time each day to maintain consistent blood levels.
• Use in combination therapy: When used with other anti-diabetic medicines (e.g., metformin, sulfonylureas, or insulin), your doctor may adjust the dose of the accompanying medication to reduce the risk of hypoglycaemia.
• Duration of use: Long-term treatment as directed by your physician. Do not stop taking the medication without consulting your doctor, even if you feel better.
• Missed dose: If you miss a dose, take it as soon as you remember on the same day. If it is almost time for your next dose, skip the missed dose and continue your regular schedule. Do not double the dose.
• Monitoring: Regular monitoring of blood glucose, HbA1c, body weight, liver function tests, and signs of fluid retention or heart failure is recommended during therapy.

Clinical Benefits:

• Improves insulin sensitivity in muscle and adipose tissue by acting as a selective agonist of PPAR-gamma, enhancing glucose uptake via GLUT4 expression and translocation.
• Reduces hepatic gluconeogenesis (glucose production by the liver), contributing to lower fasting blood glucose levels.
• Helps lower blood glucose and HbA1c, improving overall glycaemic control in patients with type 2 diabetes mellitus.
• Decreases circulating insulin levels by reversing insulin resistance, which may reduce the burden on pancreatic beta cells.
• Favourably affects lipid profile by increasing HDL cholesterol and reducing serum triglycerides, with minimal effect on LDL cholesterol, supporting cardiometabolic health when used appropriately.
• Supports comprehensive diabetes management when combined with lifestyle modifications (diet, exercise) and other prescribed medications.

Warnings & Contraindications:

• Contraindicated in patients with known hypersensitivity to pioglitazone or any component of the formulation.
• Contraindicated in patients with current or a history of heart failure (especially NYHA Class III or IV) due to risk of fluid retention and worsening cardiac function.
• Not recommended in patients with severe hepatic impairment. Baseline and periodic liver function tests are advised; discontinue if jaundice or significant liver enzyme elevation occurs.
• Use with caution in patients with edema, cardiovascular disease, or at risk of heart failure, as pioglitazone can cause fluid retention and weight gain.
• May increase the risk of bone fractures, especially in women; use with caution in patients with osteoporosis or at high risk of fractures.
• Reports have associated long-term use of pioglitazone with a possible increased risk of bladder cancer; avoid use in patients with active bladder cancer and use cautiously in those with a history of bladder cancer or unexplained hematuria.
• Not indicated for type 1 diabetes mellitus or for the treatment of diabetic ketoacidosis.
• Hypoglycaemia risk is increased when used in combination with insulin or sulfonylureas; dose adjustment of concomitant therapy may be required.
• Pregnancy and breastfeeding: Use only if clearly needed and prescribed by a physician. Insulin is generally preferred in pregnancy. Discuss risks and benefits with your doctor.
• Renal impairment: Usually can be used in mild to moderate renal impairment, but dose and monitoring should be individualized by the physician.
• Consult your doctor before use if pregnant, nursing, taking other medications, or have medical conditions such as heart disease, liver disease, kidney disease, bladder disease, edema, or osteoporosis.
• Not intended for self-medication; use only under medical supervision.
• Keep out of reach of children.

Side Effects:

• Common side effects: Weight gain, fluid retention (edema), headache, upper respiratory tract infections, sinusitis, myalgia, and mild anemia.
• Metabolic effects: May cause or worsen edema and can lead to or exacerbate heart failure in susceptible patients. When combined with other anti-diabetics, may increase the risk of hypoglycaemia (sweating, dizziness, tremor, palpitations).
• Gastrointestinal: Nausea, abdominal discomfort, or diarrhea may occur in some patients.
• Musculoskeletal: Increased risk of bone fractures, particularly in women.
• Hepatic: Rare cases of elevated liver enzymes or liver dysfunction. Seek medical attention if you experience fatigue, loss of appetite, dark urine, or yellowing of the skin or eyes.
• Genitourinary: Possible increased risk of bladder-related symptoms such as hematuria (blood in urine), dysuria, or urinary urgency. Report any persistent urinary symptoms to your doctor.
• Allergic reactions: Rash, itching, swelling, or difficulty breathing are rare but serious; seek immediate medical attention if these occur.
• Seek urgent medical attention if you develop shortness of breath, rapid weight gain, swelling of the legs or ankles, chest pain, severe abdominal pain, or signs of severe hypoglycaemia or allergic reaction.

Storage Instructions:

Store in a cool, dry place away from direct sunlight. Keep container tightly closed. Keep out of reach of children.

Specifications:

• Product type: Prescription oral anti-diabetic medicine (insulin sensitizer).
• Strength: 30 mg pioglitazone per tablet.
• Form: Tablet.
• Pack size: 30 tablets per pack (30 tab) – exact count based on the product name.
• Intended users: Adults with type 2 diabetes mellitus, as prescribed by a healthcare professional.

Disclaimer:
All pharmacy products are intended for general use only and do not replace professional medical advice, diagnosis, or treatment. Always consult a healthcare provider before use. Results may vary, and no specific outcomes are guaranteed. Products are not intended to diagnose, treat, cure, or prevent any disease unless stated. Follow label instructions carefully, as misuse may cause adverse effects. Compliance with local laws is the customer’s responsibility.